Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Cash & Equivalents (2020 - 2025)

Biofrontera has reported Cash & Equivalents over the past 6 years, most recently at $6.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $6.4 million for Q4 2025, up 8.38% from a year ago — trailing twelve months through Dec 2025 was $6.4 million (up 8.38% YoY), and the annual figure for FY2025 was $6.4 million, up 8.38%.
  • Cash & Equivalents for Q4 2025 was $6.4 million at Biofrontera, up from $3.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BFRIW hit a ceiling of $31.9 million in Q2 2022 and a floor of $1.3 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $4.4 million (2024), compared with a mean of $9.8 million.
  • Biggest five-year swings in Cash & Equivalents: soared 1518.71% in 2022 and later crashed 94.2% in 2023.
  • Biofrontera's Cash & Equivalents stood at $24.5 million in 2021, then dropped by 29.92% to $17.2 million in 2022, then crashed by 92.19% to $1.3 million in 2023, then soared by 339.69% to $5.9 million in 2024, then grew by 8.38% to $6.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $6.4 million (Q4 2025), $3.4 million (Q3 2025), and $7.2 million (Q2 2025) per Business Quant data.